The mission of the VRI is to conduct research to accelerate the development of effective vaccines against HIV/AIDS, HCV and emerging infectious diseases. The scientific goals of the VRI offer significant opportunities for innovation as they intend to:
- develop and extend the portfolio of candidate vaccines for HIV, HCV and emerging infectious diseases to be tested in clinical trials
- improve the technology of immunological testing for vaccine trials
- strengthen the partnership between immunologists, virologists, cell biologists, molecular biologists, primate model specialists and clinicians
- develop novel partnerships with industry
- pursue a social science program to analyze the specific issues related to communication on HIV vaccinology
- bring strong expertise on regulatory, legal and ethical aspects
- provide the optimal environment for improved coordination of an integrated scientific program and of dedicated funding
The VRI stems from the existing ANRS vaccine research program and includes research teams with multi-disciplinary expertise, a network of national and international thought leading scientists, core facilities, a network of clinical centers, and industry and charitable partners.
The current ongoing projects of the VRI include:
- development of vaccine candidates
- viral antigen presentation and dendritic cell (DC) biology
- immunogenicity of prime-boost strategies in non-human primate models
- study of immune correlates of protection
- phase I and II clinical trials..
With its innovative and integrated program, the VRI will develop an incentive policy for recruiting young high-potential talents, new teams and internationally recognized scientists. An attractive “starter package” will facilitate the settlement of the most promising teams within the VRI.
LEADERSHIPThe VRI is composed of a strategic committee to approve the strategic development plan of the Institute and to control its execution. The scientific committee is in charge of the scientific plan. The scientific advisory board provides the VRI with advice and evaluation of the research program.
The VRI organization is structured with 7 working divisions (work packages), including a national and international network of research teams (160+ researchers, engineers, technicians, PhD students and post-doc are contributing to its program).
The VRI represents a unique educational opportunity in the field of vaccinology and knowledge sharing.
The VRI has created a new Master degree in vaccinology in September 2015 with the objective to train students in immunology, vaccinology and the development of research products while also addressing innovation, identification of market opportunities and business and financial plans related to the development of vaccines.
FUTUREIn order to house the increasing number of research teams, a new building dedicated to biomedical research will be constructed in 2020 at the Mondor Hospital site in Créteil, on the outskirts of Paris. Benefiting from a new 4,000m2 research building, the VRI will find its physical implementation to support its development and fulfillment of its translational research model: "Gathering the skills of experimental and clinical research, from the laboratory to the patient, and vice versa, in order to develop innovative therapeutic strategies in an integrated center for research, care and training of researchers and doctors of tomorrow". This new facility will bring together scientists top teams, state-of-the-art equipment and integrated collaborative spaces that promote innovation and co-production of knowledge between public and private partners, thereby gathering a critical mass on a common site.
The new building will be designed on a modular approach to ensure high interaction between groups and to include laboratory space and seminar rooms. Large equipment will be common and accessible to all, with attractive and reference technology platforms for industrial partners and start-up; the building will be also designed to allow flexibility to accommodate new emerging technologies and facilities in the future.
- vaccine research
- basic research
- clinical, therapeutic and epidemiologic research
- research in public health and the human and social sciences
- research in developing countries..
ANRS provides funding for research projects, scholarships for graduate students and postdoctoral fellows, and also funds clinical and vaccine trials in France and developing countries. The ANRS is collaborating with the main national and international stakeholders in the fight against AIDS and viral hepatitis:
- research organizations
- hospitals and universities
- pharmaceutical companies
- private foundations.
In the developing countries where ANRS is present, the ANRS works hand in hand with local institutions and includes their researchers in project management. Since its creation, the ANRS has included community representatives in its scientific life and strategic decision-making. During the past 15 years the ANRS has conducted a comprehensive top-down program dedicated to the development of HIV vaccines.
The university has successfully united a range of disciplines which offer an exceptional program of education (ranging from technology diplomas to doctorates) and houses 31 laboratories covering almost every available field. In 2007, the university took an important further step by becoming a member of the “Université Paris-Est” Higher Education and Research Cluster, along with Paris-Est Marne-la-Vallée University, the ENPC (School of Civil Engineering), the LCPC (Civil Engineering Central Laboratory) and ESIEE-Paris (engineering school).
These establishments combine forces mainly in the area of research and doctoral schools.